Logo image
Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement
Journal article   Peer reviewed

Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement

Belinda Gray, Christopher Semsarian, Diane Fatkin, Jodie Ingles, John J Atherton, Andrew M Davis, Prashanthan Sanders, Nicholas Pachter, Jonathan R Skinner and Martin K Stiles
Heart, Lung and Circulation, Vol.29(7), pp.e85-e87
2020
Appears in  COVID-19 Research
url
https://doi.org/10.1016/j.hlc.2020.04.006View
Published Version

Abstract

COVID-19 genetic heart disease cardiomyopathy Brugada syndrome long QT syndrome catecholaminergic polymorphic ventricular tachycardia
In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. Apart from general recommendations, there are specific recommendations for the following conditions: cardiomyopathy, Brugada syndrome (including in children), long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Other recommendations are relevant to patient self-care and primary health care.

Details

Metrics

1 File views/ downloads
26 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Cardiac & Cardiovascular Systems

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image